Another Bite Out Of Apple, Eli Lilly’s Direct Approach 1/4/23
About this episode
Another day, another downgrade for Apple’s stock – the second this week. The shares are down more than 5% to start the year, as concerns over iPhone demand grow. We’ll speak to the analyst behind the latest call. Plus, Eli Lilly is taking weight-loss drugs directly to the consumer, setting up a new service to help patients get telehealth prescriptions. We’ll ask a medical doctor about the potential implications.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Power Lunch publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Power Lunch
September Rate Hike Odds, Middle East Oil Disruptions, AI Researcher Resignation...
Power Lunch
Thoma Bravo Founder, Treasury Bond Auction, Terawulf Exclusive 9/10/26
Power Lunch
Apple’s Foldable iPhone, Brent Tops $100, AT&T CEO Interview 9/9/26
Power Lunch
State of the Markets, Diesel Prices at Record Highs, Regional Bank Merger 9/8/26
Power Lunch